新公布的临床试验结果显示，spesolimab显著改善泛发性脓疱型银屑病急性发作的体征和腹泻

Spesolimab 的针灸方案还还包括迄今刚刚进行的另外两项试验。Effisayil-2 试验力图科学研究 spesolimab 作为保持稳定疗法以卫生保健 GPP 的急适度头痛。Effisayil-ON 试验是一项开放ID的五年扩展科学研究，力图科学研究 spesolimab 在 GPP 患病变里的长期疗效和相容适度。[7],[8]

关于Spesolimab

Spesolimab 是一款新HG人源化选择适度特异适度，可阻碍白介素 -36 细胞因子 (IL-36R) 的触发。IL-36通路 是免疫系统内的一种信号通路，已被证明与GPP等多种自身免疫适度结核患病的患病因有关。[i],[ii] Spesolimab是首个各种类型靶向 IL-36 通路疗法 GPP急适度头痛的在研针灸，已在一项随机、CPA来得较试验里获取了具有统计学象征意义的结果。迄今，Spesolimab还在被开发常用卫生保健GPP急适度头痛以及疗法其他贪财都可血小板适度脸部患病，如掌凶脓疱患病 (PPP) 和湿疹汗腺炎 (HS)。[11],[12]

关于在野发适度脓疱HG银屑患病

GPP 是一种罕见的、异质适度的、妨碍永生的贪财都可血小板适度脸部患病，针灸上与白斑HG银屑患病各有不同。[2],[3]GPP 是由都可血小板（一种血小板）在脸部里渗出引起的，但会引致痉挛适度的制剂适度脓疱。[3]GPP患病变的针灸患病程多种各有不同，有些患病变的结核患病患病情恶化并眩晕反复急适度头痛，而另一些患病变的结核患病持续性存有且间歇适度急适度头痛。[3]虽然 GPP急适度 头痛的相当严重总体多种各有不同，但若不马上疗法，出现败血症和多系统生殖器官衰竭等并发症，不必要妨碍永生。[6]这种慢适度全身适度结核患病但会对患病变的生活密度产生灾难性影响，并造成医护保健经济负担。GPP 在各有不同水文地区的比率多种各有不同，女适度患病变少男适度患病变。[2][13][14][15]在华南地区，基于城镇医疗保健数据库库系统进行的流行患病学科学研究辨识，2016年GPP的背比率为1.40/100000人-年。女适度患病变少男适度。

概述：

[1] Bachelez H et al. Trial of Spesolimab for Generalized Pustular Psoriasis. NEJM. 2021; XXX.

[2] Crowley JJ, et al. A brief guide to pustular psoriasis for primary care providers, Postgraduate Medicine. 2021;133(3):330-344.

[3] Navarini AA, et al. European consensus statement on phenotypes of pustular psoriasis. JEADV. 2017;31:1792-1799.

[4] Fujita H, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–1270.

[5] Sampogna F, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154(5):844–849.

[6] Jeon C, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD. 2017;Nov;3(6):495–497.

[7] ClinicalTrials.gov. A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130. Available at Accessed: September 2021.

[8] ClinicalTrials.gov. A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis. Available at: Accessed: September 2021.

[9] Furue K, et al. Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. Acta Derm Venereol. 2018;98:5–13.

[10] Bachelez H, et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019; 380:981-983.

[11] ClinicalTrials.gov. A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa. Available at: Accessed September 2021.

[12] ClinicalTrials.gov. A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab. Available at Accessed: September 2021.

[13] Ohkawara A et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996 Jan;76(1):68–71.

[14] Augey F, et al. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. European Journal of Dermatology. 2006; 16(6):669-673.

[15] Jin H, et al. Clinical features and course of generalized pustular psoriasis in Korea. The Journal of Dermatology. 2015; 42(7):674-678.